Media headlines about Novavax (NASDAQ:NVAX) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novavax earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.6778159075938 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
NVAX has been the topic of several research reports. Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 price objective on shares of Novavax in a report on Monday, December 18th. Citigroup downgraded shares of Novavax from a “buy” rating to a “neutral” rating and set a $1.00 price objective on the stock. in a report on Tuesday, December 19th. BidaskClub upgraded shares of Novavax from a “hold” rating to a “buy” rating in a report on Saturday, December 30th. B. Riley set a $2.25 price objective on shares of Novavax and gave the company a “buy” rating in a report on Friday, January 5th. Finally, S&P Equity Research decreased their price objective on shares of Novavax from $1.81 to $1.35 in a report on Wednesday, January 10th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $3.43.
NVAX stock opened at $2.02 on Friday. The company has a debt-to-equity ratio of -3.12, a quick ratio of 2.76 and a current ratio of 2.76. Novavax has a 52 week low of $0.73 and a 52 week high of $2.75. The stock has a market capitalization of $708.11, a P/E ratio of -3.21 and a beta of 2.38.
Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01). The company had revenue of $10.40 million for the quarter, compared to analyst estimates of $7.98 million. During the same quarter in the previous year, the business earned ($0.21) EPS. The business’s quarterly revenue was up 92.6% compared to the same quarter last year. analysts predict that Novavax will post -0.57 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/novavax-nvax-given-daily-media-sentiment-rating-of-0-14.html.
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.